

**Washington State Pharmacy and Therapeutics Committee  
Drug Utilization Review Board  
Date: April 21, 2021  
Time: 9 a.m. to 4 p.m.  
GoTo Webinar**

9 a.m.	Welcome & Introductions  <b>Pharmacy &amp; Therapeutics (P&amp;T) Committee Convenes (Reviews drug classes for the WA PDL)</b>	Ginni Buccola, Committee Chair
9:05 a.m.	Asthma Biologics <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Leila Kahwati, DERP
10:20 a.m.	Break	All
10:30 a.m.	TIMs: Plaque Psoriasis & Psoriatic Arthritis Crohn's Disease & Ulcerative Colitis Rheumatoid Arthritis & Ankylosing Spondylitis <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Candi Wines, DERP Shauna Durbin, DERP
11:30 a.m.	<b>Pharmacy &amp; Therapeutics Committee Adjourns</b>	Ginni Buccola, Committee Chair
11:30 a.m.	<b>Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)</b>	Ginni Buccola, Committee Chair
11:30 a.m.	ADHD/Anti-Narcolepsy Agents <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
11:40 a.m.	Allergy: Allergenic Extracts/Biologicals <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
11:50 a.m.	Anticonvulsants <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
12:05 p.m.	<b>Lunch</b>	All
12:35 p.m.	Antidementia Agents <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
12:40 p.m.	Antidepressants: GABA Receptor Modulator - Neuroactive Steroid <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
12:50 p.m.	Antiparkinson Agents <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
1 p.m.	Atopic Dermatitis Agents <ul style="list-style-type: none"> <li>• Stakeholder input*</li> </ul>	Umang Patel, Magellan

*\* Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby.  
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions  
please call Leta Evaskus at 206-521-2029.

	<ul style="list-style-type: none"> <li>• Motion</li> </ul>	
1:10 p.m.	Neuromuscular Agents: Spinal Muscular Atrophy <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
1:20 p.m.	Sleep Disorder Agents <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
1:35 p.m.	Apple Health Policy: Radicava <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Ryan Taketomo, HCA
1:55 p.m.	Break	All
2:05 p.m.	Apple Health Policy: Spinraza <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Marissa Tabile, HCA
2:25 p.m.	Apple Health Policy: Evrysdi <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Luke Dearden, HCA
2:45 p.m.	Apple Health Policy: Imidiazotetrazines- Oral <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Ryan Taketomo, HCA
3:05 p.m.	<b>Drug Utilization Review Board Adjourns</b>	Ginni Buccola, Committee Chair

*For all Apple Health (Medicaid) questions, please email [AppleHealthPharmacyPolicy@hca.wa.gov](mailto:AppleHealthPharmacyPolicy@hca.wa.gov).*

*\* Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby. Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.